Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial

Abstract

Levosimendan is a promising new inodilator agent but its effectiveness in peripartum cardiomyopathy (PPCM) has not been tested in a clinical trial. The authors sought to evaluate the effect of levosimendan therapy and to determine the predictors of clinical outcome in patients with PPCM.